Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $VTGN
Date | Price Target | Rating | Analyst |
---|---|---|---|
12/7/2023 | $15.00 | Hold → Buy | Jefferies |
8/7/2023 | $30.00 | Hold → Buy | Maxim Group |
7/22/2022 | Outperform → Neutral | Robert W. Baird | |
7/22/2022 | Buy → Hold | Jefferies | |
7/22/2022 | Outperform → Mkt Perform | William Blair |
Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update
Fasedienol U.S. registration-directed PALISADE Phase 3 Program for acute treatment of social anxiety disorder progressing with ongoing PALISADE-3, PALISADE-4 and Repeat Dose trials Vistagen highlights clinical-stage pipeline with five novel pherine product candidates with positive efficacy signals and potential to transform standards of care for multiple high prevalence indications Vistagen (NASDAQ:VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2025 third quarter ended December 31, 202
Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025
Vistagen (NASDAQ:VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Thursday, February 13, 2025 at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2025 third quarter ended December 31, 2024, and provide a corporate update. The conference call is being webcast live and a link can be found under "Events" in the Investors section of the Company's website. Participants may register for the live call link HERE to receive the dial-in numbers and uni
Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain
Vistagen (NASDAQ:VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that the U.S. Patent and Trademark Office (USPTO) granted a patent to the Company for its oral non-opioid product candidate, AV-101, for the treatment of neuropathic pain. The patent will not expire until at least 2034 and is part of Vistagen's global patent portfolio on manufacturing methods and therapeutic uses for AV-101 to treat various disorders involving the NMDA receptor. "This new patent advances our AV-101 portfolio and significantly strengthens our position for potential
VistaGen upgraded by Jefferies with a new price target
Jefferies upgraded VistaGen from Hold to Buy and set a new price target of $15.00
VistaGen upgraded by Maxim Group with a new price target
Maxim Group upgraded VistaGen from Hold to Buy and set a new price target of $30.00
VistaGen downgraded by Robert W. Baird
Robert W. Baird downgraded VistaGen from Outperform to Neutral
Chief Operating Officer Prince Joshua S. was granted 3,310 shares, increasing direct ownership by 124% to 5,981 units (SEC Form 4)
4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
CHIEF FINANCIAL OFFICER Anderson Cynthia Lynn was granted 2,592 shares, increasing direct ownership by 72% to 6,184 units (SEC Form 4)
4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
SEC Form 4 filed by Director Cunningham Ann Michelle
4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
Amendment: SEC Form SCHEDULE 13G/A filed by Vistagen Therapeutics Inc.
SCHEDULE 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)
Amendment: SEC Form SCHEDULE 13G/A filed by Vistagen Therapeutics Inc.
SCHEDULE 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)
SEC Form 10-Q filed by Vistagen Therapeutics Inc.
10-Q - Vistagen Therapeutics, Inc. (0001411685) (Filer)
Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day
Vistagen CEO Shawn Singh; The Goldie Hawn Foundation Founder Goldie Hawn; and MindUP students to ring the Nasdaq Closing Bell on October 10, 2024 Vistagen and The Goldie Hawn Foundation join forces to raise awareness around the roles of mindfulness and pioneering neuroscience in mental health Vistagen (NASDAQ:VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development of groundbreaking therapies for psychiatric disorders based on nose-to-brain neurocircuitry, and The Goldie Hawn Foundation's MindUP, a neuroscience-based preventative mental health program for youth, along with children from New York City schools utilizing MindUP, will join toget
Vistagen Appoints Cindy Anderson as Chief Financial Officer
Anderson succeeds Jerrold Dotson who is retiring after a distinguished decade-long career with Vistagen Vistagen (NASDAQ:VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced the appointment of Cindy Anderson as Chief Financial Officer (CFO), effective August 21, 2023. Ms. Anderson will succeed Jerrold Dotson, whose planned retirement was announced in July of this year. "We are delighted to welcome Ms. Anderson, an experienced and highly accomplished finance professional, to our team," said Shawn Singh, Chief Executive Officer of V
Vistagen Announces Results of Voting from 2022 Annual Meeting of Stockholders and Partial Adjournment to October 28, 2022
Annual Meeting to resume October 28, 2022 to vote on Proposal No. 5 to provide Vistagen's Board of Directors the option to implement a future reverse stock split of the Company's issued and outstanding common stock, if necessary to maintain the Company's listing on the Nasdaq Capital Market, and Proposal No. 6 to allow for an amendment to the Company's Bylaws Vistagen Therapeutics, Inc. (NASDAQ:VTGN) (the Company), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced results of voting and the partial adjournment of the Company's 2022 Annua
Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update
Fasedienol U.S. registration-directed PALISADE Phase 3 Program for acute treatment of social anxiety disorder progressing with ongoing PALISADE-3, PALISADE-4 and Repeat Dose trials Vistagen highlights clinical-stage pipeline with five novel pherine product candidates with positive efficacy signals and potential to transform standards of care for multiple high prevalence indications Vistagen (NASDAQ:VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2025 third quarter ended December 31, 202
Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025
Vistagen (NASDAQ:VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Thursday, February 13, 2025 at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2025 third quarter ended December 31, 2024, and provide a corporate update. The conference call is being webcast live and a link can be found under "Events" in the Investors section of the Company's website. Participants may register for the live call link HERE to receive the dial-in numbers and uni
Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update
Fasedienol U.S. registration-directed PALISADE Phase 3 Program for acute treatment of social anxiety disorder progressing PALISADE-3 and PALISADE-4 Phase 3 trials initiated and underway Vistagen (NASDAQ:VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today reported financial results for its fiscal year 2025 second quarter ended September 30, 2024, and provided a corporate update. "We initiated our PALISADE-4 Phase 3 trial during our second quarter, achieving yet another significant milestone in our fasedienol U.S. registration-directed Phase 3 Program for the acute treatment of social anxiety disorder," said Shawn Singh, Ch
Amendment: SEC Form SC 13G/A filed by Vistagen Therapeutics Inc.
SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)
Amendment: SEC Form SC 13G/A filed by Vistagen Therapeutics Inc.
SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)
SEC Form SC 13G/A filed by VistaGen Therapeutics Inc. (Amendment)
SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)